1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCardiac Energy Metabolism in Heart Failure is sponsored by NIH. Cardiac Energy Metabolism in Heart Failure is a Program Project Grant funded by NIH (grant number 7P01HL074237-10) that addresses the metabolic mechanisms underlying heart failure pathophysiology.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Grant Abstract: Cardiac Energy Metabolism in Heart Failure Grant Abstract: Cardiac Energy Metabolism in Heart Failure Grant Number: 7P01HL074237-10 Project Title: Cardiac Energy Metabolism in Heart Failure Abstract: This Program Project Grant addresses the metabolic mechanisms underlying the pathophysiology of heart failure (HF), and aims to identify novel metabolic approaches to prevent and treat HF.
The consequences of metabolic dysfunction in HF are poorly understood, but there is strong evidence that energy metabolism can effect contractile function and progressive left ventricular remodeling. This translational research project uses sophisticated animal models of HF to evaluate novel mechanisms that link various aspects of cardiac metabolism to clinically relevant outcomes.
This application will investigate fundamental questions about the pathophysiology of HF, and the effects of manipulating energy metabolism on cardiac function and HF progression. This Program Project is composed of four projects: Project 1: "Impact of Macronutrient Intake in Heart Failure". The effects of dietary fat, protein and carbohydrate composition on progression of HF will be investigated.
Project 2: "Heart Rate Control, Myocardial Energetics and Progression of Heart Failure". This project will dissect the role of heart rate in abnormalities of cardiac energetics and progression of LV dilation and dysfunction in HF. Project 3: "Substrate Selection and Oxidative Stress in Heart Failure".
Causal relationships will be explored between altered energy substrate metabolism and oxidative stress in HF. Project 4: "Mitochondrial Dysfunction in Heart Failure". This project investigates the molecular mechanisms for the decrease in oxidative phosphorylation found in heart and skeletal muscle mitochondria in HF.
In addition, there will be four Cores (Administrative, Large Animal/Histology, Metabolism, and Mitochondria/Mass Spec).
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments. Confirm the full requirements in the official notice before applying.
Cardiac Energy Metabolism in Heart Failure is funded by NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article